We generated two mouse strains expressing Cre-ER T2 under Flp-FRT regulation. 
ABSTRACT
Novel genetically engineered mouse models using the Cre-loxP or the Flp-FRT systems have generated useful reagents to manipulate the mouse genome in a temporally-regulated and tissue specific manner. By incorporating a constitutive Cre driver line into a mouse model in which FRT-regulated genes in other cells types are regulated by Flp-FRT recombinase, gene expression can be manipulated simultaneously in separate tissue compartments. This application of dual recombinase technology can be used to dissect the role of stromal cells in tumor development and cancer therapy. Generating mice in which Cre-ER T2 is expressed under Flp-FRT-mediated regulation would enable step-wise manipulation of the mouse genome using dual recombinase technology. Such next-generation mouse models would enable sequential mutagenesis to better model cancer and define genes required for tumor maintenance. Here, we generated novel genetically engineered mice that activate or delete
Cre-ER T2 in response to Flp recombinase. To potentially utilize the large number of Cre-loxP regulated transgenic alleles that have already been targeted into the Rosa26 locus, such as different reporters and mutant genes, we targeted the two novel Cre-ER T2 alleles into the endogenous Col1a1 locus for ubiquitous expression. In the Col1a1 FRT-Cre-ER-T2-FRT mice, Flp deletes Cre-ER T2 , so that Cre-ER T2 is only expressed in cells which have never expressed Flp.
In contrast, in the Col1a1 FRT-STOP-FRT-Cre-ER-T2 mice, Flp removes the STOP cassette to allow
Cre-ER T2 expression so that Cre-ER T2 is only expressed in cells that previously expressed
Flp. These two new novel mouse strains will be complementary to each other and will enable the exploration of complex biological questions in development, normal tissue homeostasis, and cancer.
INTRODUCTION
Genetically engineered mouse models are ideal for studying complex mammalian biological processes in vivo. Advances in genetic engineering have enabled the development of increasingly more precise, controlled manipulation of the mouse genome so that more intricate biological questions can be explored. Site-specific recombinase systems, such as the Cre-loxP and the Flp-FRT systems, were developed to allow for temporally-regulated and tissue-specific gene modification (Dymecki, 1996; O'Gorman et al., 1991; Orban et al., 1992; Sauer and Henderson, 1988) . A large number of conditional mouse alleles utilizing the CreloxP system have been generated. These include various loxP flanked genes and a number of endogenous promoter driven Cre recombinase alleles that are constitutively expressed. Cre recombinase expressed from endogenous promoters enables tissue specific deletion of DNA flanked by loxP sites to alter gene expression. The resulting tissue-specificity for recombination of the loxP sites decreases the likelihood of embryonic lethality. For example,
Villin-Cre (el Marjou et al., 2004) , which is expressed in the entire intestinal and colonic epithelium, and Fapbl 4X@-132- Cre (Saam and Gordon, 1999) , which is expressed in the distal 2/3 of the small intestine and the entire colonic epithelium, can be used to express the embryonically lethal oncogenic KRAS G12D by recombining Kras loxP-STOP-loxP-G12D (Jackson et al., 2001 ) to generate diffuse colonic hyperplasia in mice (Haigis et al., 2008) . However, gene modification in the embryo may not fully recapitulate gene manipulation in the adult to model somatic gene mutations that lead to the development of sporadic cancers. One way to circumvent this limitation is to exogenously deliver Cre recombinase to the adult mice via infection with replicative-deficient adenoviruses (Adeno-Cre) (Wang et al., 1996) . For example, intratracheal delivery of Adeno-Cre to adult mice with Rb FL/FL and p53 FL/FL mutations (Marino et al., 2000 ) generated primarily small cell lung tumors that closely
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resembled human small cell lung cancer (Meuwissen et al., 2003) . In addition to small cell lung tumors, this method also generated lung adenocarcinomas as well as medullary thyroid carcinomas both in mice that also developed small cell lung tumors and in mice that did not.
This drawback to using viral vectors, particularly in cancer biology, is due to the fact that many cell types can be infected by the adenovirus. Thus, the cancer-initiating cell (i.e. cellof-origin) can vary between tumors from different animals as well as different tumors within the same animal. This heterogeneity may lead to phenotypic differences in these mouse models of cancer. To further limit expression of Cre to specific cell types within an organ,
Cre can be expressed from the adenovirus using a cell-type specific promoter (Sutherland et al., 2011; Sutherland et al., 2014) .
Innovations in site-specific recombinase systems continue to improve tissue specificity and temporal regulation of gene expressions. For example, fusion proteins consisting of Cre recombinase and a mutated estrogen receptor that preferentially binds to the metabolites of the estrogen analog tamoxifen, such as Cre-ER T2 , have been generated (Indra et al., 1999) . These fusion proteins allow for tamoxifen-inducible Cre recombinase to translocate into the nucleus and modify the genome. These Cre-fusion proteins allow temporal activation of oncogenes and/or deletion of tumor suppressor genes in the adult mouse in a cell-type specific manner to generate cancer (Blum et al., 2013) .
Recently, a second site-specific recombination system, Flp-FRT, which originated from S. cerevisiae, has been applied to study cancer. (Lee et al., 2012; Moding et al., 2015; Moding et al., 2014; Schonhuber et al., 2014) .
The use of only one recombinase system to mutate multiple genes limits the scope of cancer research because all genetic manipulations are completed at the same time. In the case of mutations that drive cancer, the use of a single recombinase system prohibits the study of sequential mutagenesis to determine how the order of different driver gene mutations affects tumor phenotypes. Moreover, the consequence of a gene mutation at tumor initiation may be different from a mutation that is acquired later during tumor development. Indeed, when a single recombinase system is used to mutate multiple genes simultaneously, it is possible that cells may adapt to the loss of a gene at tumor initiation in ways that are different than if the same gene had been mutated later during tumor development. This may be particularly important for genetic experiments designed to identify therapeutic targets, which are required for cancer maintenance because in certain cases, inhibition of a target at the time of cancer initiation may lead to a different outcome than when a target is inhibited in an established tumor.
Others have demonstrated that the Flp-FRT and the Cre-loxP systems can be used sequentially. For example, lung adenocarcinoma has been generated by sequentially (Shai et al., 2015) . Likewise, pancreatic adenocarcinoma has been generated by sequential mutagenesis, where first Kras 
RESULTS

Generation of Flp-FRT regulated Cre-ER T2 alleles
In order to develop technology for sequential mutagenesis in vivo using two sitespecific recombinase systems, we generated Col1a1 blastocysts and male high-percentage chimeras were selected to breed with C57BL/6 females to identify germline transmission of the Cre-ER T2 alleles. The neomycin selection cassettes were removed by PhiC31 integrase-mediated recombination of the attP and attB sites in vivo by crossing the mice to the pre-existing Rosa26 PhiC31 strain (Raymond and Soriano, 2007) .
Germline transmission of Col1a1
FRT-Cre-ER-T2-FRT-NEO was verified by PCR for the construct-specific neomycin selection cassette on tail-tip DNA ( Figure 3A ). Heterozygosity for the knock-in allele was demonstrated by PCR for the wildtype Col1a1 locus ( Figure 3A ).
Successful PhiC31-mediated excision of the neomycin selection cassette was verified by PCR for gene products specific to the recombined neomycin selection cassette (excised NEO), the unrecombined neomycin selection cassette (NEO), the wildtype Col1a1 locus, and the mutant PhiC31 allele ( Figure 3B ).
Germline transmission of a single copy of Col1a1 FRT-STOP-FRT-Cre-ER-T2-NEO was verified
by PCR for the construct-specific STOP cassette, the neomycin selection cassette, and the wildtype Col1a1 locus on tail-tip DNA ( Figure 3C ). Deletion of the neomycin selection cassette by PhiC31 was verified by PCR for gene products specific for the recombined neomycin selection cassette (excised NEO), the unrecombined neomycin selection cassette (NEO), the STOP cassette, the wildtype Col1a1 locus, and the mutant PhiC31 allele ( Figure   3D ). One founder mouse for each of the novel Cre-ER T2 strains was used to propagate the colony.
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Characterization of Flp-FRT regulated Cre-ER T2 mice
To examine Cre-mediated recombination at a cellular level, tissues from Col1a1 Figure 7B ). Unexpectedly, the whole tumor tissue remained tdTomato positive without any evidence of eGFP expression. Because the STOP cassette can be appropriately removed by FlpO as shown in Figure 7A , the lack of tdTomato deletion and eGFP expression may be due to inadequate levels and/or penetration of the active tamoxifen metabolite into the tumor tissue. Therefore, alternative approaches of tamoxifen delivery were explored in subsequent cohorts. After the initial tumor was palpated in a second cohort (n=2) of Tumors were collected 10 days after the 4-hydroxytamoxifen delivery, and tdTomato and eGFP expression were evaluated by immunofluorescence ( Figure 7C ). In contrast to tumors from mice that were given intraperitoneal tamoxifen injection, the bulk tumor from mice that 
DISCUSSION
The primary mouse model is an important tool to study biological processes in vivo;
therefore, novel mouse strains and mouse models provide an opportunity for scientific advancement. Here, we have generated two novel mouse strains to facilitate more precise manipulation of the mouse genome to answer complex questions.
The two novel mouse strains take advantage of different site-specific recombinase systems to enable sequential mutagenesis separated in time and cellular location. These novel mouse strains will facilitate the study of complex questions in development, normal tissue homeostasis, and disease processes, such as cancer. For example, these strains have a number of advantages for studying the role of genes in either tumor cells or stroma. First, the knock-in alleles of both novel mouse strains are targeted to the ubiquitously expressed Col1a1 locus instead of the frequently used Rosa26 locus. This Col1a1 site was selected with the available Rosa26 knock-in alleles in mind. An advantage of knock-in alleles over other transgenic approaches that generate alleles by random integration into the mouse genome is that the precise location of the knock-in allele is known. However, each mouse can only harbor two different copies of a mutant gene at one locus. As there are many Rosa26 knock-in alleles ranging from mutant genes to fluorescent reporters, the placement of the two novel Flp-regulated Cre-ER T2 alleles at the Col1a1 locus retains the availability of both alleles of the Rosa26 locus for other genes-of-interest. of an adequate level of active tamoxifen metabolites into the tumor will be necessary to apply this system in established sarcomas. In addition to injecting 4-hydroxytamoxifen into the tumor or systemically, another approach that could be utilized is delivery of tamoxifen in the food (Schonhuber et al., 2014) .
Recently, in vivo manipulations of the mouse genome have been achieved using the CRISPR/Cas9 system to generate tumors such as those in the liver and lung via hydrodynamic injections , adenoviral delivery of both sgRNA and Cas9 two distinct mutations can be expressed in a single cell sequentially. We anticipate that this allele will provide a tightly regulated tool to study sequential mutagenesis in cancer development and to test the role of genes in tumor maintenance by mimicking therapeutic target inhibition or activation during cancer therapy.
MATERIALS AND METHODS
All animal experiments were performed according to protocols approved by the Duke University Institutional Animal Care and Use Committee.
Generation of novel mouse models
Knock-in alleles Col1a1 Col1a1 locus were injected into C57BL/6 blastocysts, which were then implanted into pseudo-pregnant mice. Male chimeras were bred to female C57BL/6 mice and the resulting progeny with brown colored coat (i.e. 129/SVJae-derived) were analyzed for germline transmission of the targeted alleles. Mice with germline transmission were crossed to the
Rosa26
PhiC31 (Raymond and Soriano, 2007) , which removed the attB/attP-flanked neomycin cassette.
Adenovirus mediated sarcomagenesis
Mouse models of soft tissue sarcoma were generated in a mixed 129/SVJae and C57BL/6 background using a combination of previously described alleles: Kras
FRT-STOP-FRT-
G12D (Young et al., 2011) , p53 FRT (Lee et al., 2012) , and Rosa26 mTmG (Muzumdar et al., 2007) .
A working solution of replication-deficient adenovirus expressing FlpO recombinase (AdenoFlpO) was generated by precipitating 25µl of Adeno-FlpO stock (University of Iowa Gene
Transfer Vector Core, Iowa City, IA) with 3µl 2M CaCl2 (Sigma-Aldrich, St Louis, MO) and 600µl MEM (Sigma-Aldrich, St Louis, MO) as previously described (Kirsch et al., 2007 ).
The working solution was then incubated at room temperature for 15 minutes prior to use.
Soft tissue sarcomas in the mouse hindlimb were generated by intramuscular (IM) injection of 50µl Adeno-FlpO working solution via a 28.5 gauge insulin syringe (BD Biosciences, Franklin Lakes, NJ). Mice were treated with a single intraperitoneal injection of tamoxifen at 75mg/kg via a 27.5 gauge insulin syringe.
4-hydroxytamoxifen and tamoxifen injections
Tumor cell isolation and culture
Sarcomas were removed after animals were sacrificed and the tumors were digested with tissue digestion buffer consisting of 5mg/ml collagenase IV (Sigma-Aldrich, St Louis, MO), 2.5U/ml dispase (BD Biosciences, Franklin Lakes, NJ), and 0.05% trypsin (Life Technologies, Carlsbad, CA) at 37ºC for 40 minutes. The resulting mixture was strained through a 70µm filter (BD Biosciences, Franklin Lakes, NJ), and filtered cells were resuspended in culture medium consisting of DMEM/F12 (Life Technologies, Carlsbad, CA) with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO), and 1x penicillin/streptomycin (Life Technologies, Carlsbad, CA).
Polymerase chain reactions
DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen, Venlo, Limburg) and PCR experiments were performed with a C1000 Touch Thermal Cycler (Bio-Rad, Hercules, CA). Nucleic acid concentrations were measured using NanoDrop 1000 (Thermo Scientific, Waltham, MA). The location of the primer sequences relative to the targeted alleles are shown in Figure 3 and the sequences are as follows: 
PhiC31 PCR was performed using primers as previously described (Raymond and Soriano, 2007) .
One touchdown PCR program was used for all reactions: 1) melting at 94ºC for 180 seconds; 2) for 15 cycles, melting at 94ºC for 45 seconds, annealing at 64ºC for 45 seconds with -0.5ºC per cycle, elongating at 72ºC for 60 seconds; 3) for 25 cycles, melting at 94ºC for 45 seconds, annealing at 57ºC for 45 seconds, elongating at 72ºC for 60 seconds; 4) elongating at 72ºC for 600 seconds.
Frozen sectioning and immunofluorescence
For frozen sectioning, tumor and tissue specimens were dissected, embedded in OCT (Tissue-Tek, Torrance, CA), and frozen over dry ice. Frozen specimens and 10µm sections generated via a cryostat (Leica Microsystems, Wetzlar, Germany) were stored unfixed in - 
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RESOURCE IMPACT Background
The Cre-loxP and, more recently, the Flp-FRT recombinase systems are widely used to generate transgenic mouse models to study a variety of human diseases, including cancer.
One major drawback of these tools is that for each of the individual systems, the genetic mutations are generated at the same time, which limits the scope of questions that can be explored. Multiple recombinase systems can be combined to better temporally-and spatiallyrestrict gene mutations in in vivo models.
Results
To develop a Cre-loxP and Flp-FRT dual recombinase system that allows for more controlled manipulation of the mouse genome, the authors generated Col1a1 and Col1a1 mice. The Col1a1 locus was chosen to allow both copies of the Rosa26 locus to be used for existing alleles targeted to the Rosa26 locus. For example, these strains will be valuable tools to study sequential mutagenesis in cancer progression and the roles of genes in mediating tumor maintenance and response to therapy. 
